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Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection results in a spectrum
of clinical presentations. Evidence from Africa indicates that significantly less COVID-19 patients suffer from
serious symptoms than in the industrialized world. We and others previously postulated a partial explana-
tion for this phenomenon, being a different, more activated immune system due to parasite infections. Here,
we aimed to test this hypothesis by investigating a potential correlation of co-infection with parasites with
COVID-19 severity in an endemic area in Africa.
Methods: Ethiopian COVID-19 patients were enrolled and screened for intestinal parasites, between July 2020 and
March 2021. The primary outcome was the proportion of patients with severe COVID-19. Ordinal logistic regres-
sion models were used to estimate the association between parasite infection, and COVID-19 severity. Models
were adjusted for sex, age, residence, education level, occupation, body mass index, and comorbidities.
Findings: 751 SARS-CoV-2 infected patients were enrolled, of whom 284 (37.8%) had intestinal parasitic infection.
Only 27/255 (10.6%) severe COVID-19 patients were co-infected with intestinal parasites, while 257/496 (51.8%)
non-severe COVID-19 patients were parasite positive (p<0.0001). Patients co-infected with parasites had lower
odds of developing severe COVID-19, with an adjusted odds ratio (aOR) of 0.23 (95% CI 0.170.30; p<0.0001) for
all parasites, aOR 0.37 ([95% CI 0.260.51]; p<0.0001) for protozoa, and aOR 0.26 ([95% CI 0.190.35];
p<0.0001) for helminths. When stratified by species, co-infection with Entamoeba spp., Hymenolepis nana, Schis-
tosoma mansoni, and Trichuris trichiura implied lower probability of developing severe COVID-19. There were 11
deaths (1.5%), and all were among patients without parasites (p = 0.009).
Interpretation: Parasite co-infection is associated with a reduced risk of severe COVID-19 in African patients. Para-
site-driven immunomodulatory responses may mute hyper-inflammation associated with severe COVID-19.
Funding: European and Developing Countries Clinical Trials Partnership (EDCTP)  European Union, and
Joep Lange Institute (JLI), The Netherlands.
Trial registration: Clinicaltrials.gov: NCT04473365
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Research in context
Evidence before this study
We searched PubMed, medRxvi, and bioRxiv for [“parasite” OR
“helminth” OR “Protozoa”] AND [“COVID-1900 OR “SARS-CoV-
200] until April 12, 2021, with no language restriction. Ecological
studies reported an inverse correlation between incidence of
COVID-19 and parasites, like with soil-transmitted helminths,
schistosomiasis, or malaria. Some reports proposed that hel-
minth co-infection may modulate, or mute COVID-19 severity
in endemic regions. To the best of our knowledge, there are no
reports published to date actually demonstrating a clear associ-
ation between parasite co-infection and COVID-19 severity.
Added value of this study
In this unique cohort study consisting of 751 Ethiopian patients,
we determined the association between co-infection with para-
sites and COVID-19 severity. We identified 284 (37.8%) COVID-
19 patients to be co-infected with one or more parasites. We
demonstrate that the proportion of COVID-19 patients with
parasitic infection decreased with increasing categories of dis-
ease severity. When stratified by species-specific parasite co-
infection status, we observed same trends. Using a multivari-
able logistic regression analysis, and after adjusting for sex, age,
residence, and the presence of comorbidities, we observed that
co-infection with any parasite, including protozoa, or hel-
minths, was associated with lower odds of developing severe
COVID-19. In addition, patients without parasite co-infection
appeared vulnerable to worse in-hospital outcomes, including
admission to the intensive-care unit, requirement for supple-
mental oxygen, or mechanical ventilation, and death.
Implications of all the available evidence
Co-infection with parasites is associated with reduced develop-
ment of severe COVID-19 in this Africa setting. Our findings
confirm the hypothesis that co-infection with parasites may
mute hyper-inflammation associated with severe COVID-19.
Further research is needed to unravel underlying immunology
and consequences for SARS-CoV-2 vaccination in Africa. Impli-
cations might involve COVID-19 vaccine efficacy in Africa.
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Infection with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) results in a spectrum of clinical presentations. Whereas
most people with COVID-19 develop asymptomatic or mild illness,
at-risk patients can develop severe pneumonia and hypoxemia dis-
ease requiring hospitalization [13]. In severe cases, COVID-19 can
be complicated by acute respiratory distress syndrome (ARDS), sepsis,
multi-organ failure, including acute kidney injury, and cardiac injury
[25]. Risk factors for a severe disease course and mortality due to
COVID-19 include older age, immune compromise, and underlying
co-morbidities, particularly non-communicable diseases (NCDs), such
as hypertension, cardiovascular disease and diabetes [25].
Low and medium-income countries (LMICs) differ significantly in
disease prevalence and conditions from high-income countries
(HICs). Infectious diseases have a markedly higher prevalence in
LMICs, including so-called neglected infectious diseases (NIDs).
Amongst NIDs, parasitic infections affect more than 2 billion people
throughout the world, with disproportionately high prevalence rates
in resource-poor settings [6,7]. Multicellular and highly complexparasites such as Ascaris, hook worm, Trichuris, Enterobius, and Schis-
tosoma, as well as unicellular organisms including Entamoeba, Giar-
dia, Toxoplasma, Cyclospora and Cryptosporidia are among the major
organisms that contribute to the global intestinal parasitic disease
burden [6,7].
Chronic and/or persistent parasitic infections are common in
LIMCs, and such chronic infections, possibly in part through direct
modulation of the host’s immune responses, were shown to alter
clinical outcomes to other infections [8,9]. Pre-existing parasitic
infections may also modify the host’s immune response to infection
with SARS-CoV-2, with postulated beneficial and detrimental effects
[1013]. To the best of our knowledge, no studies to date have
assessed the possible association between parasitic co-infection and
COVID-19 disease severity. We and other previously hypothesized
parasite infections to skew the immune system towards TH2
responses, thus precluding TH1 hyper immune activation that is
characteristic of COVID-19 severity [1113]. The objective of this
study was to test this hypothesis by comparing the parasitic infec-
tions of COVID-19 patients stratified for clinical outcomes.
2. Methods
2.1. Study design and participants
This study is part of Profile-CoV project (Clinicaltrials.gov:
NCT04473365), a prospective observational cohort study being
undertaken in two sites in Ethiopia, with the aim of profiling of
immunological response to SARS-CoV-2 in the context of persistent
immune activation in Sub-Saharan Africa. This study included indi-
viduals who were recruited for Profile-CoV and subsequently
screened them for intestinal parasitic infections.
2.2. Procedures
Individuals presenting to the Kuyha (Mekelle University College of
Health Sciences, Mekelle), and Eka Generalized Hospital (Addis
Ababa) who qualified for testing were screened for SARS-CoV-2 infec-
tion with a nasopharyngeal swab, and real-time polymerase chain
reaction (RT-PCR). Following the declaration by the WHO that
COVID-19 became pandemic, the Ethiopian Ministry of Health imple-
mented a mass screening of all travelers, people who had come in
contact with COVID-19 patients, those from high risk settings (e.g.
health-care workers), as well as those with symptoms suggestive of
COVID-19. All patients with confirmed SARS-CoV-2 infection were
admitted to dedicated COVID-19 Isolation and Treatment Centers.
Patients were admitted irrespective of clinical severity status.
Whereas 515 patients were included from Kuyha Hospital in Mekelle
between July and October 2020, the 236 cases from Eka Generalized
Hospital in Addis Ababa were enrolled between February and March
2021. Admitted patients, if symptomatic, received supportive therapy
according to their clinical need. Patients with severe disease received
high-flow oxygen via nasal cannula or intubation as well as dexa-
methasone. Whereas patients admitted to the intensive care unit
(ICU) were followed every day, or as needed, those with asymptom-
atic or mild/moderate clinical presentation were quarantined, and
followed every 35 days, or as needed up until discharge.
Sociodemographic, clinical, and laboratory data were collected
using standardized Case Record Forms (CRFs) adapted from the Inter-
national Severe Acute Respiratory and Emerging Infection Con-
sortium’s (ISARIC) CRFs for emerging severe acute respiratory
infections [14]. Patient’s clinical status was stratified following the
WHO criteria as asymptomatic, mild/moderate, severe (with dys-
pnea, respiratory rate  30 breaths per minute, O2 saturation  93%,
lung infiltrates  50% of the lung fields within 2448 h), and critical
(with respiratory failure, septic shock, and/or multiple organ failure)
[15]. All data were then entered into electronic medical records.
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obtained from nasopharyngeal swabs, according to manufacturer’s
instructions (TIB Molbiol, Berlin, Germany). Fresh stool sample speci-
mens were obtained for examination for parasites and ova. Analysis
included direct microscopic examination and modified Ritchie con-
centration method [16]. In addition, the intensity of infection was
determined using Kato-Katz method and was calculated and reported
as individuals’ eggs per gram of feces (EPG), as described previously
[16], and recommended by the WHO [17]. All patients who were pos-
itive for intestinal parasites received parasite-specific therapy. None
of these patients received ivermectin.
The study protocol was reviewed and approved by the Health
Research Ethics Review Committee of Mekelle University College of
Health Sciences (No.: ERC 1769/2020), the Ethiopian Public Health
Institute (No.: EPHI 6.13/814), and Eka Kotebe General Hospital (No.:
EK/150/5/32). Written informed consent was obtained by all partici-
pants, or their guardians, for participation in the study.
2.3. Outcomes
The primary outcome for this study was the proportion of severe
COVID-19 among SARS-CoV-2 positive patients with and without a
parasitic co-infection. Asymptomatic and mild/moderate COVID-19
cases were classified as non-severe cases and severe and critical
COVID-19 cases were classified as severe. Secondary outcomes
included requirement for supplemental oxygen, and/or mechanical
ventilation, admission to ICU, and death.
2.4. Statistical analysis
We hypothesized that co-infection with intestinal parasite is asso-
ciated with reduced risk of severe COVID-19 [13]. Exposure was
intestinal parasite co-infection. The primary outcome of the study
was the proportion of severe disease among SARS-CoV-2 PCR positive
patients. A feasibility study showed that about 20% of COVID-19
patients with parasite co-infection developed severe COVID-19. We
expected this to increase to about 50% among those without parasite
co-infection. A minimum sample size of 223 patients with parasite,
and 446 without parasite co-infection (at 1:2 ratio) was required to
ensure 80% power using a two-sided test with a significance level of
a=0.05. Assuming a dropout rate of 10%, a minimum total sample
size of 738 was estimated for the cohort.
Baseline characteristics for continuous variables were expressed
as the median with interquartile range (IQR), and for categorical vari-
ables as proportions. Whereas categorical variables were compared
using x2 test or Fisher’s exact test, continuous variables were com-
pared by Mann-Whitney U, or Kruskal-Wallis tests, as appropriate.
Normality of distribution of variables was ascertained by running
Wilk test of normality, before analysis by Mann-Whitney U, or Krus-
kal-Wallis tests. The association between COVID-19 severity and par-
asitic co-infection was determined by ordinal logistic regression
analysis. Independent variables, including age, sex, residence, comor-
bidity, parasite infection (overall and dis-aggregated by parasite type
into protozoa, helminths, and species level), were included in the ini-
tial univariate analysis. We included sex, age, education level, occu-
pation, pregnancy, body mass index and comorbidities as
confounding factors as they have been associated with poor clinical
outcomes among patients with COVID-19 [25]. In addition, we
adjusted for urban vs. rural residence as this has been shown to influ-
ence differential immune responses [18]. A multivariate regression
analyses [adjusted odds ratio (aOR)] were calculated by including all
variables that were p<0.05 by univariate analysis. P values <0.05
were considered statistically significant. Data was analyzed using
STATA (Statistical package v. 14.0, StataCorp, Texas, USA). Reporting
of this study was undertaken according to the STROBE statement
(Supplemental Table 4).2.5. Role of funding source
Funders had no role in the study design, study participant selec-
tion, and recruitment, data collection, analysis, data interpretation,
decision to publish, or preparation of the manuscript.
3. Results
3.1. Study population characteristics
A total of 881 COVID-19 cases were recruited and 130 were
excluded, either due to incomplete data or inadequate stool samples,
or patient not able to provide sample (Fig. 1). Baseline socio-demo-
graphic data of the study participants is summarized in Table 1. The
majority of the study population was male (63.9%). The median age
of the cohort was 37 (IQR 2850; range 392) years, with 53.0%
being in the age range of 24 to 44 years. Those older than 60 years
and above comprised only 16.1%. Patients were hospitalized for a
median of 12 days (range: 3 to 45 days). Notably, 36.2% of the cohort
was asymptomatic, and 29.8% had mild/moderate symptoms at the
time of diagnosis; the remaining 29.0% and 4.9% had severe, and criti-
cal disease (requiring admission to the ICU), respectively (Supple-
mental Table 1).
Patients with severe, or critical disease at presentation were older
and had more symptoms, including fever, dyspnoea, cough, hemop-
tysis, chest pain, sore throat, head ache, nausea/vomiting, abdominal
pain, diarrhea, and myalgia, when compared to those presenting
with asymptomatic, or mild/moderate clinical status (Supplemental
Table 1). Nasal congestion, and loss of smell/taste was reported less
frequently in severe, or critical cases. Co-morbid conditions were sig-
nificantly higher among severe, and critical COVID-19 cases when
compared to non-severe cases (Supplemental Table 1). In addition,
COVID-19 patients with NCDs were older, the majority (45.3%) being
 60 years old (p = 0.0001), and more symptomatic (Supplemental
Table 2). Severe/critical clinical manifestation was more frequent in
COVID-19 patients with NCDs compared to those without NCDs
[(p<0.0001), Supplemental Table 2].
3.2. Prevalence of intestinal parasites
Of the total 751 individuals enrolled in the study, 284 (37.8%) har-
bored one or more intestinal parasites (Table 2). Of the patients
included in the study, protozoa and helminth infections comprised
20.2% and 24.5%, respectively. The most common protozoa infections
were Entamoeba spp. (16.8%) and Giardia (3.6%). For helminths, the
most common infections were H. nana (15.1%), S. mansoni (4.5%), and
A. lumbricoides (3.6%). The proportion of patients harboring multiple
parasites (>1) was 8.7% (Table 2). There was no significant difference
in sex and age distribution between those with parasites and those
without (Table 1). However, those without parasite co-infection
appeared more symptomatic for COVID-19. In addition, the propor-
tion of comorbid conditions, in particular NCDs, was significantly
higher in COVID-19 patients without parasitic co-infection (Table 1).
3.3. Association of parasitic co-infection with COVID-19 severity
The proportion of severe, or critical COVID-19 was significantly
higher in patients without parasitic co-infection (Table 1). The pro-
portion of severe COVID-19 in patients without parasites (196/467
[42.0%, CI 37.5646.52]) was significantly higher than in those with
parasites (22/284 [7.8%, CI 5.1411.51]); p<0.0001. Likewise, the
proportion of critical COVID-19 in patients without any parasite
infection (32/467 [6.9%, CI: 4.889.54]) was significantly higher than
in those co-infected with parasites (5/284 [1.8, CI 0.734.18];
p<0.0001). The proportion of severe COVID-19 was higher in the in
the non-protozoa group (206/599 [34.4%, CI 30.6838.30]) when
Fig. 1. Flow diagram of study participants.
Table 1
Clinical features among COVID-19 patients without, or with parasite co-infection.
Characteristic All patients n = 751 Without parasite n = 467 With parasite n = 284 p-Value
Sociodemographic features:
Gender
Male 480 (63.9%) 307 (65.7%) 173 (60.9%) 0.011
Female (not pregnant) 257 (34.2%) 147 (31.5%) 110 (38.7%)
Female (pregnant) 14 (1.9%) 13 (2.8%) 1 (0.4%)
Age in years 37 (2850) 40 (3057) 32 (2542) 0.064
Age group [years]
< 24 92 (12.3%) 42 (9.0%) 50 (17.6%) 0.0001
24  44 398 (53.0%) 224 (48.0%) 174 (61.3%)
45  59 140 (18.6%) 99 (21.2%) 41 (14.4%)
 60 121 (16.1%) 102 (21.8%) 19 (6.7%)
Residence
Rural 141(18.8%) 68 (14.6%) 73 (25.7%) 0.0001
Urban 593 (79.0%) 393 (84.2%) 200 (70.4%)
Undetermined 17 (2.3%) 6 (1.3%) 11 (3.9%)
Education level
 Primary 215 (28.6%) 124 (26.5%) 91 (32.0%) 0.210
Secondary 203 (27.0%) 126 (27.0%) 77 (27.1%)
College/university 333 (44.3%) 217 (46.5%) 116 (40.9%)
Occupation
Unemployed 250 (33.3%) 149 (31.9%) 101 (35.6%) 0.587
Employed 421 (56.0%) 267 (57.2%) 154 (54.2%)
Health care workers 80 (10.7%) 51 (10.9%) 29 (10.2%)
Clinical symptoms and signs:
Fever 248 (33.0%) 200 (42.8%) 48 (16.9%) <0.0001
Dyspnea 199 (26.5%) 176 (37.7%) 23 (8.1%) <0.0001
Cough (any type) 339 (45.1%) 259 (55.5%) 80 (28.2%) <0.0001
Nonproductive cough 148 (19.7%) 94 (20.1%) 54 (19.0%) 0.0001
Productive cough 191 (25.4%) 165 (35.3%) 26 (9.2%)
Hemoptysis 21 (2.8%) 19 (4.1%) 2 (0.7%) 0.007
Chest pain 47 (6.3%) 39 (8.4%) 8 (2.8%) 0.002
Sore throat 70 (9.3%) 54 (11.6%) 16 (5.6%) 0.007
Head ache 223 (29.7%) 181 (38.8%) 42 (14.8%) <0.0001
Nasal congestion 42 (5.6%) 23 (4.9%) 19 (6.7%) 0.307
Loss of smell and/or taste 59 (7.9%) 36 (7.7%) 23 (8.1%) 0.847
Nausea/vomiting 76 (10.1%) 67 (14.4%) 9 (3.2%) <0.0001
(continued)
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Table 1 (Continued)
Characteristic All patients n = 751 Without parasite n = 467 With parasite n = 284 p-Value
Abdominal pain 44 (5.9%) 35 (7.5%) 9 (3.2%) 0.014
Diarrhea 39 (5.2%) 32 (6.9%) 7 (2.5%) 0.009
Myalgia 112 (14.9%) 98 (21.0%) 14 (4.9%) <0.0001
Body mass index
18.524.9 668 (88.9%) 399 (85.4%) 269 (94.7%) <0.0001
<18.5 4 (0.5%) 3 (0.6%) 1 (0.4%)
25.029.9 56 (7.5%) 42 (9.0) 14 (4.9%)
30.0 23 (3.1%) 23 (4.9%) 0 (0.0%)
Temperature > 37.3 °C 50 (6.7%) 41 (8.8%) 9 (3.2%) 0.003
Temperature 36.0 (36.036.9) 36.2 (36.037.0) 36.0 (3636.7) <0.00001
Systolic blood pressure (mmHg) 120 (110130) 120 (110130) 115 (110125) 0.0009
Diastolic blood pressure (mmHg) 75 (6880) 75 (6880) 75 (6880) 0.8395
Respiratory rate (breaths/minute) 22 (2025) 23 (2128) 22 (1923) <0.00001
Heart rate (beats/minute) 85 (7694) 86 (7896) 83 (7690) <0.00001
Laboratory data*
Lymphocyte, x109/L 1.2 (0.81.6) 1.2 (0.81.6) 1.3 (0.91.7) 0.7008
Hematocrit,% 44.0 (40.146.9) 44.2 (40.647.4) 42.4 (38.245.7) 0.0296
Platelet count, x109 /L 217 (163294) 215 (159288) 247(204334) 0.0488
Alanine aminotransferase concentration, U/L 40 (2567) 40 (2567) 48 (3655) 0.6841
Creatinine concentration, mg/dL 0.87 (0.681.04) 0.88 (0.701.04) 0.62 (0.481.47) 0.0135
Comorbidities
Comorbidity (at least 1) 216 (28.8%) 178 (38.1%) 38 (13.4%) <0.0001
Noncommunicable disease (NCDs) comorbidities 179 (23.8%) 150 (32.1%) 29 (10.2%) <0.0001
Diabetes 97 (12.9%) 84 (18.0%) 13 (4.6%) <0.0001
Hypertension 87 (11.6%) 74 (15.9%) 4.6 (4.5%) <0.0001
Cardio vascular diseases 19 (2.5%) 18 (3.9%) 1 (0.4%) 0.003
Chronic obstructive lung diseases and asthma 23 (3.1%) 19 (4.1%) 4 (1.4%) 0.040
Chronic liver disease 8 (1.1%) 8 (1.7%) 0 (0.0%) 0.027
Chronic kidney disease 11 (1.5%) 9 (1.9%) 2 (0.7%) 0.176
Surgery cases 15 (2.0%) 12 (2.6%) 3 (1.1%) 0.151
Communicable disease comorbidities
HIV 17 (2.3%) 14 (0.3.0%) 3 (1.1%) 0.083
Tuberculosis 1 (0.1%) 1 (0.2%) 0 (0.0%) 0.435
Outcomes
Admission to ICU 56 (7.5%) 44 (9.4%) 12 (4.2%) 0.009
Supplemental oxygen 243 (32.4%) 216 (46.3%) 27 (9.5%) <0.0001
Invasive mechanical ventilation 53 (7.1%) 46 (9.9%) 7 (2.5%) <0.0001
Death 11 (1.5%) 11 (2.4%) 0 (0.0%) 0.009
Severe COVID19 255 (34.0%) 228 (48.8%) 27 (9.5%) <0.0001
Data are expressed as n (%) or median (IQR). p values are from x2 test, or Fisher’s Exact test (for categorical variables), and Mann-Whitney U, or
Kruskal-Wallis tests (for continuous variables), as appropriate.
*Data missing for 490, 487, 492, 622, and 540 patients for lymphocyte, hematocrit, platelet, alanine aminotransferase, and creatinine concentra-
tions, respectively.
Table 2
Prevalence of parasitic infections in the different COVID19 severity category.
Parasite coinfection All patients (n = 751) COVID-19 severity category p-Value
Asymptomatic (n = 272) Mild/moderate (n = 224) Severe (n = 218) Critical (n = 37)
Any parasite 284 (37.8%) 150 (55.2%) 107 (47.8%) 22 (10.1%) 5 (13.5%) <0.0001
Protozoa  all 152 (20.2%) 77 (28.3%) 59 (26.3%) 12 (56.5%) 4 (10.8%) <0.0001
Entamoeba spp. cyst 109 (14.5%) 63 (23.2%) 38 (17.0%) 6 (2.8%) 2 (5.4%) <0.0001
Entamoeba histolytica trophozoite 17 (2.3%) 5 (1.8%) 10 (4.5%) 2 (0.9%) 0 (0.0%) 0.087
Giardia lamblia cyst 12 (1.6%) 4 (1.5%) 4 (1.5%) 2 (0.9%) 2 (5.4%) 0.227
Giardia lamblia trophozoite 15 (2.0%) 6 (2.2%) 7 (3.1%) 2 (0.9%) 0 (0.0%) 0.393
Helminth  all 184 (24.5%) 103 (37.9%) 68 (30.4%) 12 (5.5%) 1 (2.7%) <0.0001
Hymenolepis nana 113 (15.1%) 59 (21.7%) 47 (21.0%) 7 (3.2%) 0 (0.0%) <0.0001
Schistosoma mansoni 34 (4.5%) 22 (8.1%) 10 (4.5%) 2 (0.9%) 0 (0.0) 0.001
Ascaris lumbricoides 27 (3.6%) 13 (4.8%) 10 (4.5) 3 (1.4%) 1 (2.7%) 0.142
Trichuris trichiura 11 (1.5%) 8 (2.9%) 3 (1.3%) 0 (0.0%) 0 (0.0%) 0.050
Hook worm 12 (1.6%) 8 (2.9%) 3 (1.3%) 1 (0.5%) 0 (0.0%) 0.169
Taenia spp. 3 (0.4%) 3 (1.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.239
Soiltransmitted helminths only 48 (6.4%) 26 (9.6%) 17 (7.6%) 4 (1.8%) 1 (2.7%) 0.002
Polyparasitism  any 65 (8.7%) 37 (13.6%) 25 (11.2%) 3 (1.4%) 0 (0.0%) <0.0001
Protozoa plus helminth 50 (6.7%) 30 (11.0%) 18 (8.1%) 2 (0.9%) 0 (0.0%) <0.0001
Helminth plus helminth 19 (2.5%) 11 (4.0%) 7 (3.1%) 1 (0.5%) 0 (0.0%) 0.046
Data are expressed as n (%). P values are from x2 test, or Fisher’s Exact test, as appropriate.
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Fig. 2. Relationship of parasite co-infection with categories of COVID-19 severity. Pro-
portion of patients with different categories of COVID-19 severity co-infected with any
parasite, protozoa, or helminths. Error bars indicate 95% CI. p<0.0001 (for parasite, and
protozoa), and p = 0.001 (for helminths) by Kruskal-Wallis rank test.
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p<0.0001), and in the helminth negative group (206/567 [36.3%, CI
32.4640.39]) compared to the helminth co-infected group (12/184
[6.5%, CI 3.7211.19]; p = 0.0001). Furthermore, the proportion of
critical COVID-19 cases was higher in the in the non-protozoa group
(33/599 [5.5%, CI 3.947.66]) when compared to the protozoa group
(4/152 [2.6%, CI 0.986.87]; p<0.0001), and in the helminth negative
group (36/567 [6.4%, CI 4.618.69]) compared to the helminth co-
infected group (1/184 [0.5%, CI 0.083.82]; p = 0.0001). We did not
observe any correlation between helminth egg-load and COVID-19
severity.
Thus, parasitic infections were inversely correlated with COVID-
19 severity. A higher proportion of patients without parasitic co-
infection were admitted to the ICU, required supplemental oxygen,
and/or mechanical ventilation, or died compared to those with para-
sitic co-infection (Table 1). The proportion of COVID-19 patients with
any parasite infection, or protozoa, or helminth infection decreased
with increasing categories of disease severity (Table 2; Fig. 2). When
stratified by species-specific parasite co-infection status, we observed
similar trends with significant decrease in COVID-19 severity for
those co-infected with poly-parasites, soil-transmitted helminths,
Entamoeba spp. cyst, H. nana, S. mansoni, and T. trichiura compared to
those without (Supplemental Fig. 1).
Ordinal logistic regression analysis was used in order to ascertain
the association between parasite infection and COVID-19 severity. In
univariate analysis, male sex, age  60 years, urban residence, pri-
mary education level, being overweight, or obese, and comorbidities,
in particular, NCDs including diabetes, hypertension, cardio-vascular
diseases, and chronic liver disease were all associated with increased
odds of severe COVID-19 (Table 3). However, occupation, pregnancy,
chronic obstructive lung disease, including asthma, chronic kidney
disease, surgery, and HIV-1 infection appeared not associated with
severe COVID-19. In contrast, having any parasitic, protozoal, or hel-
minth infection was associated with lower odds of developing severe
COVID-19. In multivariate analysis, age  60 years, urban residence,
obesity, comorbidity, in particular NCDs including hypertension, and
chronic liver disease were associated with increased odds of severe
COVID-19 (Table 3). After adjustment for sex, age, residence, obesity,
and the presence of comorbidities, COVID-19 patients with any para-
sitic co-infection (aOR 0.35 [95% CI 0.260.48]; p<0.0001), protozoal
co-infection (aOR 0.51 [95% CI 0.360.73]; p<0.0001), as well as hel-
minth co-infection (aOR 0.37 [95% CI 0.270.52]; p<0.0001) had a
lower odds of developing severe COVID-19 when compared to
patients without a parasitic co-infection (Table 3). We also noted that
harboring multiple parasites was strongly associated with less severeCOVID-19 (aOR 0.43 [95% CI 0.260.71]; p<0.0001; Table 3). Further
analysis stratified by parasite species level revealed that patients co-
infected with Entamoeba cyst spp (aOR 0.39 [95% CI 0.260.58];
p<0.0001), or Hymenolepis nana (aOR 0.49 [95% CI 0.330.73];
p<0.0001), or Schistosoma mansoni (aOR 0.42 [95% CI 0.210.86;
p = 0.017)], or T. trichiura (aOR 0.17 [95% CI 0.040.78); p = 0.023) co-
infection tended to have lower odds of developing severe COVID-19
(Fig. 3). Covid-19 patients co-infected with Hook worm also tended
to exhibit decreased risk of severe disease, but this was not statisti-
cally significant (Fig. 3). Smaller sample sizes precluded observations
for the remaining parasite species. We could not determine associa-
tion between death (n = 11), and (lack-of) co-infection with parasites
because of the small number of death outcomes. Notably, after
adjusting for sex, age, residence, pregnancy, education, occupation,
and body mass index we found that the odds of having a NCD was
significantly lower in COVID-19 patients with parasitic co-infection
(aOR 0.35 [95% CI 0.210.60], p<0.0001), or helminth infection (aOR
0.21 [95% CI 0.100.43]; p<0.0001; Supplemental Table 3).
4. Discussion
This study demonstrates for the first time that co-infection with
enteric parasites, both protozoa and helminths, is associated with
lower odds of developing severe COVID-19 in African patients. Nota-
bly, this association was maintained even after adjusting for sex, age,
residency, education level, and presence of comorbid conditions, fac-
tors that are commonly associated with COVID-19 severity [25].
Previous reports have demonstrated that helminthic infection corre-
lates with a lower risk for development of diabetes, and metabolic
syndrome in humans [1924]. This is consistent with our finding
that patients co-infected with parasites had lower proportions of
NCDs. This finding suggests that the inverse correlation between par-
asitic infection and COVID-19 severity in our cohort can be attributed
at least partly to decreased NCDs risk. In this study, we noted that
NCDs, in particular hypertension, chronic liver disease, overweight,
and obesity were all associated with increased risk of COVID-19
severity. Nonetheless, pregnancy, and NCDs such as chronic obstruc-
tive lung disease, chronic kidney disease, surgery, and HIV-1 infection
appeared not associated with severe COVID-19, most likely due to the
smaller sample size of patients with these conditions.
The pathogenesis of severe COVID-19 has been linked to the phe-
nomenon of immune hyperactivation [25], which resembles that of
chronic inflammatory condition, such as hypertension, obesity, dia-
betes, and inflammatory bowel diseases [2628]. Lifestyle factors,
such as high calorie diet, physical inactivity, and higher standard of
living, coupled with decreased rates of helminthic infections, in HICs
has been linked with the advent of chronic inflammatory conditions
 compatible with the theory of hygiene hypothesis [29,30]. Indeed,
several authorities proposed that lack of co-infection with parasites
may lead to increased risk of COVID-19 severity in HICs [1113,
29,30]. It is possible, therefore, that parasites mute COVID-19 severity
through their effects in modulating systemic immune response.
Chronic intestinal parasitic infections are often associated with the
development of T helper-2 (TH2)-skewed, alternatively activated
macrophages (M2), and type 2 innate lymphoid cells. These
responses are accompanied with the induction of cytokines such as
IL-4, IL-5, IL-13, and enhanced eosinophilia, and IgE responses [8,9].
Parasite-driven TH-2 responses are important in controlling parasitic
infections, as well as play an important role in the repair of tissue
damage as a result of parasite infections [8,9]. TH2 immune responses
during parasitic infections is also accompanied by the induction of a
strong T cell regulatory (Treg) responses that is relevant for survival
and chronic persistence of the parasite itself, that may affect
responses to heterologous infection [8,9,29]. On the contrary, severe
COVID-19 is associated with increased hyperinflammation character-
ized by increased production of pro-inflammatory cytokines [25].
Table 3
Factors associated with severe COVID19.
Characteristic Univariable model Multivariable model
Unadjusted OR (95% CI) p-Value Adjusted OR (95% CI) p-Value
Gender
Male 1 .. 1 ..
Female (not pregnant) 0.70 (0.530.92) 0.011 0.86 (0.641.15) 0.313
Female (pregnant) 1.72 (0.694.28) 0.242 2.09 (0.795.59) 0.139
Age (60 years vs. <60) 8.08 (5.4511.97) <0.0001 3.41 (2.135.46) <0.0001
Rural vs. urban residence 0.38 (0.280.516) <0.0001 0.52 (0.380.72) <0.0001
Education level
 Primary 1 .. 1 ..
Secondary 0.60 (0.420.86) 0.006 1.02 (0.681.54) 0.911
College/university 0.91 (0.661.25) 0.569 .. ..
Occupation
Unemployed 1 .. 1 ..
Employed 1.01 (0.761.35) 0.939 .. ..
Health care workers 1.26 (0.811.94) 0.304 .. ..
Body mass index
18.524.9 1 .. 1 ..
<18.5 0.52 (0.046.34) 0.610 .. ..
25.029.9 4.68 (2.96 7.40) <0.0001 1.34 (0.612.94) 0.460
30.0 14.44 (8.1225.69) <0.0001 2.68 (1.225.87) 0.014
Comorbidity (at least 1)* 8.27 (5.9211.55) <0.0001 5.43 (3.5048.42) <0.0001
Noncommunicable disease (NCDs) comorbidities* 10.58 (7.3615.20) <0.0001 7.74 (4.6412.90) <0.0001
Diabetes 6.41 (4.229.76) <0.0001 1.61 (0.783.32) 0.198
Hypertension 9.63 (6.1015.18) <0.0001 2.87 (1.635.907) <0.0001
Cardio vascular diseases 5.27 (2.3711.74) <0.0001 1.25 (0.5043.12) 0.633
Chronic obstructive lung diseases 1.90 (0.904.04) 0.093 .. ..
Chronic kidney disease 2.13 (0.726.74) 0.174 .. ..
Chronic liver disease 3.57 (1.0.811.78) 0.037 4.67 (1.3016.82) 0.018
Surgery cases 0.64 (0.251.66) 0.362 .. ..
Communicable disease comorbidities
HIV 2.05 (0.835.07) 0.121 ..
Tuberculosis 1.82e+09 (....) 0.998 .. ..
Parasite coinfection**
Any parasite (at least 1) 0.23 (0.170.30) <0.0001 0.35 (0.260.48) <0.0001
Protozoa 0.37 (0.260.51) <0.0001 0.51 (0.360.73) <0.0001
Helminth 0.26 (0.190.35) <0.0001 0.37 (0.270.52) <0.0001
Polyparasitism  any 0.31 (0.190.51) <0.0001 0.43 (0.260.71) 0.001
Protozoa plus helminth 0.29 (0.170.50) <0.0001 0.36 (0.200.65) 0.001
Helminth plus helminth 0.33 (0.140.79) 0.013 0.52 (0.211.25) 0.143
Soiltransmitted helminths only 0.39 (0.230.68) 0.001 0.43 (0.240.77) 0.004
OR=odds ratio. *Adjusted for gender, age, residence, education level, body mass index; **Adjusted for gender, age, residence, education level, body
mass index, and comorbidities.
Fig. 3. ORs for the association between species-specific parasite co-infection and COVID-19 severity. All models and those stratified by species-specific parasitic co-infection were
analysed by univariable ordinal logistic regression analysis. *Multivariable models adjusted for sex, age, residence, education, body mass index, and comorbiditiesy (including diabe-
tes, hypertension, cardio-vascular diseases, and chronic liver diseases). ORs=odds ratios. Lines are 95% CIs.
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may counterbalance overactive TH1 responses, which have been
described in severe COVID-19 [13]. In addition, parasite-driven gut
microbiome changes may modulate the host’s immune response
[13]. Thus, it is possible that parasitic infections may affect pathogen-
esis both through direct modulation of the immune system as well as
through an indirect parasite-driven microbiome balance [8,9,13].
Indeed, it has been demonstrated in animal models that enteric hel-
minths can protect against pulmonary viral infections through inter-
action with microbiota [31]. Paradoxically, lack of hygienic practice
in parasite endemic areas of LMICs may increase the risk of transmis-
sion and infection of SARS-CoV-2 [29].
The strengths of the current study include its prospective nature.
However, our study has some limitations. First, it was not possible to
collect stool samples for every consecutive patient which may have
resulted in a potential selection bias. Second, stool examination was
determined by microscopy only. Although PCR has been shown to be
superior to microscopy with increased sensitivity and specificity [32],
the presence of very low intensity of infection determined by PCR,
might indeed preclude the effects on immune modulation. Third,
some of the parasite species-specific associations with COVID-19
severity could not be ascertained in the current study because of
small sample sizes/prevalence. Fourth, it is difficult to ascertain
whether the cases included in our study can be considered represen-
tative of the wider population, given the fact that there is lack of data
from the country. Finally, the inclusion of a smaller proportion of crit-
ical cases (which are rare in our settings) [33], as compared to other
categories within the clinical spectrum of COVID-19 in our cohort
may potentially bias the results. Confounding through other treat-
ments the patients may have received on their COVID-19 severity in
our cohorts is negligible, as very few patients (n = 5) took remdesivir.
In addition, none of the patients co-infected with parasites included
in the cohort did receive anti-parasitic drug ivermectin, that has been
shown to exhibit in-vitro activity against SARS-CoV-2 [34].
In conclusion, our study is the first to show a significant inverse
correlation between the presence of intestinal parasites and COVID-
19 severity, suggesting that parasite co-infection, with both protozoa
and helminths, may protect against progression to severe COVID-19.
This is corroborated by the observed low COVID-19 fatality rate in
LMIC settings where parasitic infections are endemic [11,12]. None-
theless, causality cannot be inferred from the current study design.
Thus, more evidence corroborating this association is needed, with
corroboration in other LMIC settings, and studies with larger sample
sizes that permit testing of possible interplay between the parasite
microbiome on COVID-19 severity [13]. Unraveling the parasite-
modulated mechanisms underlying severe COVID-19 offers avenues
for novel preventive and therapeutic interventions. Moreover, para-
sitic infections might have repercussions for efficacy of current
COVID-19 vaccines administered in Africa through COVAX initiative
[35], and could lead to alternative approaches, such as: first deworm,
than vaccinate. Studies in this area are recommended.5. Contributors
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